MTOR and small cell lung carcinoma: Figure 1, B and C, presents an example of drug response and synergy heatmaps, in which JQ1 synergized with everolimus in a broad dose range of 39.1–312.5 nmol/L. No synergy was observed at the JQ1 dose greater than or equal to 625 nmol/L due to a strong single-agent activity (≤ 16% viable). Figure 1D and Supplemental Table 2 list 22 drugs that are synergistic with JQ1 and I-BET762 in more than or equal to 3 out of the 4 SCLC cell lines, with inhibitors targeting the PI-3K–AKT–mTOR pathway at the top of the list.